XTalks

OCTOBER 1, 2020

Leaving academia for industry is a route that academic scientists and professors did not traditionally pursue in the past due to perceived differences in skillsets, experiences and even associated stigmas. WeiQi Lin, MD, PhD, executive vice president of research & development and principal scientist, DURECT Corporation.

Scientist 52

Scientist In-Vitro Research Life Science 52

The Pharma Data

JANUARY 27, 2021

Bruker is one of the world’s leading analytical instrumentation companies providing high-performance scientific instruments and high-value analytical and diagnostic solutions to scientists globally. 28, 2021 09:19 UTC. CAMBRIDGE & WETHERBY, England & BILLERICA, Mass.–(

Reagent 52

Reagent In-Vitro FDA Approval Development 52

pharmaphorum

JANUARY 25, 2022

The Toronto-based company already counts many of the world’s largest pharma companies among its customers, using its platform for a range of tasks such as improving reagent and antibody selection to help scientists run more successful experiments, drawing on data from published studies and organisations’ internal databases.

Life Science 52

Life Science Reagent Pharma Companies Scientist 52

XTalks

JANUARY 20, 2021

Access to laboratory reagents, equipment and research subjects is a necessity for researchers to complete their experimental work, as well as care for live cells, plants or animals. To keep these workers safe, employers have implemented social distancing protocols in the workplace, for employees and customers alike.

Research 97

Research Reagent Marketing Packaging 97

XTalks

APRIL 22, 2022

Receptor occupancy assays have been developed and applied in both nonclinical and clinical studies to provide insight into PK/PD relationships so far,” said Andre Olsson, PhD, Senior Scientist, Flow Cytometry at the global contract research organization (CRO) Medpace. The Benefits of Receptor Occupancy in Clinical Trials.

Clinical Trials 98

Clinical Trials Clinical Trials Trials Antibody 98

Advarra

NOVEMBER 29, 2022

Bottlenecks in the manufacturing process, supply chain issues such as accessibility of good manufacturing practice (GMP)-grade reagents, and shortages of qualified scientists and engineers have caused many therapies to fail at critical stages of the clinical development pipeline. But review issues are not the only problems.

Gene Therapy 52

Gene Therapy Gene Production Clinical Trials 52

Pharmaceutical Technology

FEBRUARY 3, 2023

With scientists fervently developing mRNA vaccines, nucleic acid therapeutics, and viral vector-based gene therapies, clinicians are set to have a growing number of tools available to treat a wide range of conditions, from infectious diseases to genetic disorders and more. The field of genomic medicine has reached a true turning point.

Genome 244

Genome Genomics Medicine Gene Therapy 244

XTalks

AUGUST 18, 2020

Instead of RNA extraction, the Yale test involves use of a reagent that when mixed with a saliva sample and heated for a short period of time, releases the viral genome for subsequent detection with PCR. Having a test that requires less reagents and resources, such as the RNA extraction kits, increases capabilities for increased testing.

FDA Approval 90

FDA Approval Reagent RNA Genome 90

pharmaphorum

FEBRUARY 3, 2021

Dr Jennifer Harbottle, senior scientist in the R&D Base Editing team of PerkinElmer’s Horizon Discovery business, looks at progress made in the realms of biotechnology and next-generation diagnostics, vaccines and therapeutics, including the application of CRISPR-Cas9 gene editing in developing and refining cell therapies.

Gene Editing 98

Gene Editing Gene DNA Engineer 98

XTalks

JUNE 27, 2022

BD says it offers a “suite of open system reagents for the BD MAX System that enables labs to fully automate and streamline their Lab Developed Tests, and BD can partner with customers to develop complementary assays on the system.”.

Development 83

Development In-Vitro Reagent Vaccination 83

The Pharma Data

JANUARY 22, 2021

The Biden team said it had identified 12 “immediate supply shortfalls” that have been critical to the pandemic response, including N95 surgical masks and isolation gowns, as well as swabs, reagents and pipettes used in testing, the Times reported. COVID variants might lessen power of vaccines.

Vaccination 52

Vaccination Vaccine Antibody Reagent 52

The Pharma Data

JANUARY 21, 2021

The Biden team said it had identified 12 “immediate supply shortfalls” that have been critical to the pandemic response, including N95 surgical masks and isolation gowns, as well as swabs, reagents and pipettes used in testing, The New York Times reported. COVID variants might lessen power of vaccines.

Vaccination 52

Vaccination Vaccine Antibody Reagent 52